# US 2022/0088157 A1 · Methods for treating headache

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088157 A1
- Document ID: US20220088157A1
- Status: Published application
- Kind: A1
- Application number: 17/457,091
- Filed: 2021-12-01
- Published: 2022-03-24
- Earliest claimed: 2004-02-26
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Catherine C. Turkel; Mitchell F. Brin
- Web page: https://patentgrep.com/patent/US20220088157A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.

## Claims

### Claim 1

A method for reducing the occurrence or alleviating a headache in a patient in need thereof, the method comprising local administration by injection of a composition comprising a botulinum toxin type A, wherein the number of injection sites is 23 to 58, the number of muscle areas injected is 6 to 7 and the botulinum toxin type A dose is 105 to 260 units, and wherein at least the frontal/glabellar, occipitalis, temporalis, semispinalis, splenius capitis and trapezius muscles are injected.

### Claim 2 (depends on 1)

The method of claim 1, wherein the headache is a migraine headache.

### Claim 3 (depends on 1)

The method of claim 1, wherein the headache is a non-migraine headache.

### Claim 4 (depends on 3)

The method of claim 3, wherein the administration is subdermal or subcutaneous.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration is intramuscular.

### Claim 6 (depends on 1)

The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C1, D, E, F and G.

### Claim 7 (depends on 1)

The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.
